NCT03209219View on ClinicalTrials.gov

Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

August 31, 2020

Study Completion Date

January 31, 2021

Conditions
Behçet DiseaseUveitis
Interventions
DRUG

Interferon Alfa-2A

3×10\^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter

DRUG

Cyclosporine Pill

100mg， oral, bid

Trial Locations (1)

100730

Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT03209219 - Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis | Biotech Hunter | Biotech Hunter